"The skull acts as a bastion of privacy; the brain is the last private part of ourselves," Australian neurosurgeon Tom Oxley says from New York. Oxley is the CEO of Synchron, a neurotechnology company born in Melbourne that has successfully trialled hi-tech brain implants that allow people to send emails and texts purely by thought. In July this year, it became the first company in the world, ahead of competitors like Elon Musk's Neuralink, to gain approval from the US Food and Drug Administration (FDA) to conduct clinical trials of brain computer interfaces (BCIs) in humans in the US. Synchron has already successfully fed electrodes into paralysed patients' brains via their blood vessels. The electrodes record brain activity and feed the data wirelessly to a computer, where it is interpreted and used as a set of commands, allowing the patients to send emails and texts.

BERLIN – A turning point for Rafael Yuste, a neuroscientist at New York's Columbia University, came when his lab discovered it could activate a few neurons in a mouse's visual cortex and make it hallucinate. The mouse had been trained to lick at a water spout every time it saw two vertical bars, and researchers were able to prompt it to drink even with no bars in sight, said Yuste, whose team published a study on the experiment in 2019. "We could make the animal see something it didn't see, as if it were a puppet," he said in a phone interview. "If we can do this today with an animal, we can do it tomorrow with a human for sure." Yuste is part of a group of scientists and lawmakers, stretching from Switzerland to Chile, who are working to rein in the potential abuses of neuroscience by companies from tech giants to wearable startups.